KR102753455B1 - 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법 - Google Patents

암 및 자가면역 질환을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102753455B1
KR102753455B1 KR1020217006602A KR20217006602A KR102753455B1 KR 102753455 B1 KR102753455 B1 KR 102753455B1 KR 1020217006602 A KR1020217006602 A KR 1020217006602A KR 20217006602 A KR20217006602 A KR 20217006602A KR 102753455 B1 KR102753455 B1 KR 102753455B1
Authority
KR
South Korea
Prior art keywords
cancer
cells
delete delete
gitr
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217006602A
Other languages
English (en)
Korean (ko)
Other versions
KR20210041036A (ko
Inventor
라마찬드란 무랄리
랜달 맥널리
신레이 판
존선 유
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Priority to KR1020257000546A priority Critical patent/KR20250025409A/ko
Publication of KR20210041036A publication Critical patent/KR20210041036A/ko
Application granted granted Critical
Publication of KR102753455B1 publication Critical patent/KR102753455B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
KR1020217006602A 2018-08-08 2019-08-08 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법 Active KR102753455B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257000546A KR20250025409A (ko) 2018-08-08 2019-08-08 암 및 자가면역 질환을 치료하기 위한 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862716101P 2018-08-08 2018-08-08
US62/716,101 2018-08-08
PCT/US2019/045742 WO2020033715A1 (en) 2018-08-08 2019-08-08 Compositions and methods for treating cancer and autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257000546A Division KR20250025409A (ko) 2018-08-08 2019-08-08 암 및 자가면역 질환을 치료하기 위한 조성물

Publications (2)

Publication Number Publication Date
KR20210041036A KR20210041036A (ko) 2021-04-14
KR102753455B1 true KR102753455B1 (ko) 2025-01-10

Family

ID=69415674

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217006602A Active KR102753455B1 (ko) 2018-08-08 2019-08-08 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법
KR1020257000546A Pending KR20250025409A (ko) 2018-08-08 2019-08-08 암 및 자가면역 질환을 치료하기 위한 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257000546A Pending KR20250025409A (ko) 2018-08-08 2019-08-08 암 및 자가면역 질환을 치료하기 위한 조성물

Country Status (7)

Country Link
US (1) US20210299176A1 (https=)
EP (1) EP3833323A4 (https=)
JP (2) JP7530346B2 (https=)
KR (2) KR102753455B1 (https=)
CN (2) CN112739314A (https=)
CA (1) CA3108796A1 (https=)
WO (1) WO2020033715A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy
CN113429488B (zh) * 2021-07-14 2022-08-30 海正生物制药有限公司 GITR/TGF-β双靶向融合蛋白及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368349A1 (en) 2014-05-28 2015-12-24 4-Antibody Ag Anti-GITR Antibodies and Methods of Use Thereof
US20170260594A1 (en) 2014-12-30 2017-09-14 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ZA200509143B (en) * 2003-05-23 2007-03-28 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
TW200800230A (en) * 2006-03-31 2008-01-01 Dynamis Therapeutics Inc Composition and method related to fructosamine-3-kinase inhibitors
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
PL3242947T3 (pl) 2015-01-09 2021-01-11 Oncosec Medical Incorporated Terapia genowa i elektroporacja do leczenia zmian złośliwych

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368349A1 (en) 2014-05-28 2015-12-24 4-Antibody Ag Anti-GITR Antibodies and Methods of Use Thereof
US20170260594A1 (en) 2014-12-30 2017-09-14 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal for ImmunoTherapy of Cancer, 5:47/1-12, 2017.*

Also Published As

Publication number Publication date
JP2024156758A (ja) 2024-11-06
KR20250025409A (ko) 2025-02-21
KR20210041036A (ko) 2021-04-14
WO2020033715A1 (en) 2020-02-13
EP3833323A1 (en) 2021-06-16
EP3833323A4 (en) 2022-08-10
JP7530346B2 (ja) 2024-08-07
US20210299176A1 (en) 2021-09-30
CA3108796A1 (en) 2020-02-13
JP2021534110A (ja) 2021-12-09
CN118662499A (zh) 2024-09-20
CN112739314A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
JP7807108B2 (ja) 治療用細胞の活性化及び排除のための二重コントロール
JP7587528B2 (ja) Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
CN108350062B (zh) 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
US20250011380A1 (en) Methods of treating aging-related disorders
JP2024156758A (ja) 癌及び自己免疫疾患を治療するための組成物及び方法
KR20230125204A (ko) 항원 특이적인 t 세포 및 이의 제조 및 이용 방법
AU2022268348B2 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
KR20230031280A (ko) 노화 관련 장애의 치료 방법
US20250121026A1 (en) Compositions and methods for treating fibrosis
CA3197255A1 (en) Binding proteins recognizing ha-1 antigen and uses thereof
TW202408538A (zh) Stat降解劑及其用途
US20220370586A1 (en) Method of generating activated t cells for cancer therapy
TW202500126A (zh) 雜環化合物及其用途
CN118510797A (zh) 识别hpv16 e7抗原的结合蛋白和其用途
AU2026202388A1 (en) Methods of treating aging-related disorders
CN117425665A (zh) 包含mhc i类肽的方法和组合物
JP2025527729A (ja) テザリングされたインターロイキン２組み換え受容体及び使用方法
CN120302989A (zh) Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
HK40068347A (en) Overexpression of immunoproteasome in host cells for generating antigen-presenting cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

P12-X000 Request for amendment of application rejected

St.27 status event code: A-2-2-P10-P12-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601